ADMA Biologics, Inc.ADMANASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank93
5Y CAGR+1.4%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

5Y CAGR
+1.4%/yr
Long-term compound
Percentile
P93
Near historical high
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025162.66%
2024-45.06%
2023-8.69%
2022-0.88%
2021-38.28%
2020152.02%
2019-40.30%
2018-36.98%
2017-18.97%
20169.58%